News report 📈 Stocks 🌍 United States

Cathie Wood Adds to Meta, Airbnb, and Beam Therapeutics Amid Market Shifts

Cathie Wood continues her aggressive growth strategy, purchasing shares of Meta, Airbnb, and Beam Therapeutics as she capitalizes on recent price movements and long-term growth potential.

🕐 1 min read

3 assets impacted (Stocks). Net bias: 3 Bullish, 0 Bearish, 0 Neutral. Strongest signal: META ↑ 8/10 (68% confidence).

📊 Affected Assets (3)

META
Bullish 🤖 68%
📅 Short-term 🌍 US · Explicit

Cathie Wood added to Meta as the stock surged 11% on strong Muse app adoption and a Wells Fargo price target hike.

ABNB
Bullish 🤖 65%
📅 Short-term 🌍 US · Explicit

Cathie Wood bought more Airbnb despite regulatory and travel headwinds, as the company continues double-digit revenue growth.

BEAM
Bullish 🤖 62%
📅 Short-term 🌍 US · Explicit

Cathie Wood bought Beam Therapeutics after a clinical data selloff, encouraged by the accelerated approval pathway for BEAM-302.

🎯 Key Takeaways

  • Meta shares rallied 11% following the successful launch of the Muse AI app and a Wells Fargo price target hike to $796.
  • Airbnb maintains double-digit revenue growth despite regulatory headwinds and rising travel costs.
  • Beam Therapeutics saw increased interest from Wood after a clinical data selloff, with the company now pursuing an accelerated FDA approval pathway for BEAM-302.

📝 Executive Summary

Ark Invest CEO Cathie Wood expanded her positions in Meta Platforms, Airbnb, and Beam Therapeutics following recent market volatility. Wood leveraged Meta's 11% surge driven by Muse app adoption, Airbnb's resilient revenue growth, and a dip in Beam Therapeutics to bolster her portfolio's exposure to emerging tech and biotech.

❓ FAQ

Why did Cathie Wood increase her stake in Meta Platforms?

Wood added to her Meta position following an 11% single-day stock surge, fueled by the rapid adoption of the company's new Muse AI app and an optimistic price target upgrade from Wells Fargo.

What is the outlook for Beam Therapeutics after its recent stock decline?

Despite a selloff following clinical data updates, Beam Therapeutics is pursuing an accelerated approval pathway for its BEAM-302 candidate, which Wood views as a strategic entry point.